New Jersey Alliance for Clinical Translational Science: NJ ACTS

新泽西临床转化科学联盟：NJ ACTS

• 批准号: 10201004
• 负责人: Reynold Alexander Panettieri
• 金额: $ 148.2万
• 依托单位: RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-11 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10201004
• 关键词: AIDS/HIV problem; Address; Affect; Age; Asian Indian; Behavioral; Biometry; Child; Chronic Disease; Clinical; Clinical Data; Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Design; Cohort Studies; Collaborations; Communities; Cuban; Databases; Dental; Development; Diagnosis; Diagnostic; Discipline of Nursing; Disease Management; Diverse Workforce; Elderly; Electronic Health Record; Evaluation; Fluorescent in Situ Hybridization; Fostering; Foundations; Government; Growth; Health; Health Insurance Portability and Accountability Act; Health Sciences; Health system; Healthcare; Hospitals; Image; Improve Access; Individual; Industry; Informatics; Infrastructure; Institutes; Institutional Review Boards; Intervention; Investigation; Investments; Laboratories; Leadership; Life Style; Link; Location; Longevity; Low income; Machine Learning; Medicaid; Medical; Mentors; Methodology; Methods; Minority; Minority Groups; Mission; Muslim population group; Neighborhood Health Center; New Jersey; Not Hispanic or Latino; Ontology; Oral health; Outpatients; Parents; Participant; Pathogenesis; Patient Recruitments; Perception; Population; Population Density; Precision therapeutics; Prediction of Response to Therapy; Preventive Intervention; Process; Public Health; Public Health Schools; Recording of previous events; Research; Research Personnel; Research Training; Resources; School Nursing; Science; Solid; South Asian; Special Populations Research; Substance abuse problem; Technology; Therapeutic; Therapeutic Intervention; Training; Translational Research; Universities; Vision; Workforce Development; analytical tool; base; biomarker discovery; career development; catalyst; clinical care; clinical database; clinical investigation; cognitive neuroscience; cohesion; community based participatory research; disease heterogeneity; ethnic diversity; ethnic minority population; follower of religion Jewish; improved; industry partner; innovation; interdisciplinary approach; logarithm; medical schools; member; natural language; next generation; novel; novel strategies; population health; programs; racial diversity; racial minority; recruit; relating to nervous system; research clinical testing; response; severe mental illness; skills; success; tool; translational scientist; treatment response; trial design

Contact PD/PI: Panettieri, Reynold Alexander Project Summary/Abstract Overview Coordinated by Rutgers Biomedical and Health Sciences (RBHS), the New Jersey Alliance for Clinical and Translational Science (NJ ACTS) comprises a consortium with Rutgers and Princeton Universities (PU), NJ Institute for Technology (NJIT), medical, nursing, dental and public health schools, hospitals, community health centers, outpatient practices, industry, policymakers and health information exchanges. All Alliance universities and affiliates have provided substantial resources and contributed to the planning, development and leadership of the consortium. With access to ~7 million people, NJ ACTS serves as a ‘natural laboratory’ for translational and clinical research. With a state population of ~9 million, New Jersey ranks 11th in the US, 1st in population density and higher than average in racial and ethnic diversity. Surprisingly, NJ has no CTSA Hub to coordinate translational and clinical research. Our CTSA Hub focuses on two overarching themes: the heterogeneity of disease pathogenesis and response to treatment, and the value of linking large clinical databases with interventional clinical investigations to identify cause-and-effect and predict therapeutic responses. NJ ACTS will provide: innovative approaches to link information from large databases and electronic health records to inform clinical trial design, execution and analysis; and novel platforms for biomarker discovery using fluorescence in situ hybridization and machine learning to identify unique neural signatures of chronic illness. NJ ACTS will access a large health system with significant member diversity; a rich legacy of community engagement and community-based research platforms; and proven approaches to enhance workforce development in clinical research. With a substantial investment in streamlining research administration and IRB practices at Rutgers and with the inception of NJ ACTS, there exists an unparalleled opportunity for logarithmic growth in clinical research in New Jersey. To build our capacity for participant and clinical interactions as a CTSA Hub, the newly established Trial Accelerator and Recruitment Office will coordinate feasibility assessment, implementation, recruitment, and evaluation of clinical studies. Additionally, our organization of five clinical research units into a cohesive network provides extraordinary expertise in strategic locations to enhance participant recruitment from diverse communities with a particular focus on: children; the elderly; those with serious mental illness or substance abuse issues; low-income individuals served by Medicaid; those with HIV/AIDS; and people of all ages who are minorities, underserved, and victims of health and environmental disparities. With a history of collaboration, partners and affiliates share unique skills, expertise, training and mentoring capabilities that will be greatly amplified within the infrastructure of a CTSA Hub. Princeton and NJIT, without medical schools or hospital affiliates, seeks collaboration with Rutgers to provide clinical research platforms; Rutgers seeks the PU and NJIT expertise in novel informatics platforms, expertise in natural language and ontology, machine learning and cognitive neurosciences. Together NJ ACTS will provide an alliance that will catalyze clinical research and training across New Jersey to improve population health and contribute to the CTSA Consortium. In this revised application, the overall themes remain unchanged but Cores leadership and direction has been markedly refined. Page 337 Project Summary/Abstract Contact PD/PI: Panettieri, Reynold Alexander New Jersey Alliance for Clinical and Translational Science (NJ ACTS)

联系PD/PI：Panettieri，Reynold Alexander 项目摘要/摘要 概述 由罗格斯生物医学和健康科学（RBHS）协调，新泽西州临床和 转化科学（NJ ACTS）包括一个与罗格斯和普林斯顿大学（PU）的财团，NJ 技术研究所（NJIT），医学，护士，牙科和公共卫生学校，医院，社区健康 中心，门诊实践，行业，政策制定者和健康信息交流。所有联盟大学 分支机构提供了大量资源，并为计划，发展和领导力做出了贡献 NJ ACT可以使用约700万人，作为翻译的“天然实验室” 和临床研究。新泽西州的州人口约为900万，在美国排名第11，人口排名第一 种族和种族多样性的密度和高于平均水平。令人惊讶的是，新泽西州没有CTSA集线器可以协调 翻译和临床研究。我们的CTSA中心重点关注两个总体主题： 疾病的发病机理和对治疗的反应，以及将大型临床数据库与 介入的临床研究以识别因果关系并预测治疗反应。新泽西州的行为会 提供：链接大型数据库和电子健康记录信息的创新方法以告知 临床试验设计，执行和分析；以及使用荧光在生物标志物发现的新型平台 原位杂交和机器学习以识别慢性疾病的独特神经特征。新泽西州的行为会 访问具有重大成员多样性的大型卫生系统；社区参与的丰富遗产和 基于社区的研究平台；并证明可以增强临床劳动力发展的方法 研究。通过简化罗格斯的研究管理和IRB实践的大量投资 随着NJ行为的成立，存在无与伦比的临床对数增长的机会 新泽西州的研究。为了建立我们作为CTSA枢纽的参与和临床互动的能力，新的 成立的试验加速器和招聘办公室将协调可行性评估，实施， 招募和临床研究评估。此外，我们将五个临床研究单位组织成一个 凝聚力网络在战略地点提供了非凡的专业知识，以增强参与者的招聘 具有特定关注的不同社区：儿童；较早的患有严重精神疾病的人或 药物滥用问题；医疗补助服务的低收入个人；患有艾滋病毒/艾滋病的人；和所有人 少数群体，服务不足和健康和环境差异的受害者。有历史 合作，合作伙伴和分支机构具有独特的技能，专业知识，培训和心理功能 在CTSA集线器的基础设施中大大放大。普林斯顿和NJIT，没有医学院或 医院分支机构，寻求与Rutgers合作以提供临床研究平台；罗格斯寻求PU 以及新颖信息平台，自然语言和本体专业知识，机器学习方面的NJIT专业知识 和认知神经科学。 NJ Acts共同提供一个联盟，将催化临床研究和 在新泽西州进行培训，以改善人口健康并为CTSA财团做出贡献。在此修订中 应用，总体主题保持不变，但核心领导和指导已得到明显完善。 第337页 项目摘要/摘要 联系PD/PI：Panettieri，Reynold Alexander 新泽西州临床和转化科学联盟（NJ ACTS）